Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $0.19 on Friday. The firm has a market capitalization of $11.61 million, a price-to-earnings ratio of -0.06 and a beta of 1.06. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.68. The company’s 50 day moving average price is $0.31 and its 200 day moving average price is $0.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.